ArticleFrontiers in microbiology2022
Identification of MYH9 Key Domain Involved in the Entry of PRRSV Into Permissive Cells.
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluation of Celastrol Antiviral Activity Against Equid Alphaherpesvirus Type 8 Infection.Viruses · 2025Article
- Host combats porcine reproductive and respiratory syndrome virus infection at non-coding RNAs level.Virulence · 2024Review
- Mechanism of PRRSV infection and antiviral role of polyphenols.Virulence · 2024Review
- Hyperoside inhibits EHV-8 infection via alleviating oxidative stress and IFN production through activating JNK/Keap1/Nrf2/HO-1 signaling pathways.Journal of virology · 2024Article
- Heme oxygenase-1 is an equid alphaherpesvirus 8 replication restriction host protein and suppresses viral replication via the PKCβ/ERK1/ERK2 and NO/cGMP/PKG pathway.Microbiology spectrum · 2024Article
- Rutin prevents EqHV-8 induced infection and oxidative stress via Nrf2/HO-1 signaling pathway.Frontiers in cellular and infection microbiology · 2024Article
- Role of microRNAs in host defense against porcine reproductive and respiratory syndrome virus infection: a hidden front line.Frontiers in immunology · 2024Review
- Recombinant characteristics and pathogenicity of a novel PRRSV variant in weaned piglets derived from recombination of three clinical epidemic strains.Frontiers in veterinary science · 2024Article
- Blebbistatin as a novel antiviral agent targeting equid herpesvirus type 8.Frontiers in veterinary science · 2024Article
- Cobalt Protoporphyrin Blocks EqHV-8 Infection via IFN-α/β Production.Animals : an open access journal from MDPI · 2023Article
- Review
- Editorial: Porcine reproductive and respiratory syndrome virus - animal virology, immunology, and pathogenesis.Frontiers in immunology · 2023Article
- The Antiviral Activity of Caprylic Monoglyceride against Porcine Reproductive and Respiratory Syndrome Virus In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important pathogen that causes huge losses economically to the pig industry worldwide. Previous research suggested that receptor dependence is necessary for PRRSV infection. MYH9 and CD163 are indispensable for PRRSV entry into a porcine alveolar macrophage. In the present study, human MYH9 (hMYH9) and mouse MYH9 (mMYH9), similar to swine MYH9, could also accelerate PRRSV infection in pCD163-mediated cell lines. Knockdown of MYH9 activity using the specific small interfering RNA or inhibitor (blebbistatin) concomitantly decreased PRRSV infection. C-terminal fragment of MYH9 (PRA) proteins from different mammalian species contains a conserved binding domain (aa1676-1791) for PRRSV binding, since the recombinant MYH9
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.